Morgan Stanley cut its price target for Bicycle Therapeutics plc (BCYC) to between $12 and $13.17 per share, maintaining an equal-weight rating.
The change matters to investors because BCYC trades on the Nasdaq and a lower target can pressure the stock, affecting portfolio allocations and market sentiment. Analysts said the adjustment reflects a strategic refocus of the company's drug pipeline, which could alter future earnings expectations.
The revision was first reported on April 8, 2024 in a TheFly note that Morgan Stanley distributed to clients, and it was echoed in a Yahoo Finance article that quoted the bank’s internal memo [1]. The memo confirmed that the equal-weight rating remains unchanged, signalling that the firm still views the stock as a neutral‑to‑positive position despite the target reduction.
The two reports differ — Yahoo Finance lists a new target of $12 per share, down from $13 [1], while MSN cites a revised target of $13.17 per share [2]. Both sources agree the target is lower than previous estimates, but the exact figure varies between the outlets.
MSN further notes that the $13.17 target represents a 29.27% decrease from a prior estimate of $18.62 that Morgan Stanley issued on Feb. 21, 2026 [2]. Yahoo Finance, however, referenced only the earlier $13 figure as the former target, without mentioning the larger drop. The discrepancy highlights how analysts may update forecasts at different intervals, leading to divergent published numbers.
Morgan Stanley said the revision stems from a refocus of Bicycle Therapeutics' pipeline, which now emphasizes later‑stage candidates over earlier‑phase projects. The shift suggests the firm is prioritizing assets with clearer regulatory pathways and nearer‑term revenue potential, a factor that can affect valuation models used by investors.
Overall, the lowered targets signal that the market may need to temper expectations for near‑term growth, but the retained Equal Weight rating indicates that Morgan Stanley still sees the stock as a steady component of a diversified portfolio.
“Morgan Stanley lowered its price target for BCYC to between $12 and $13.17 per share.”
What this means: The downgrade suggests investors should expect slower short‑term earnings growth from Bicycle Therapeutics, while the unchanged Equal Weight rating implies the stock remains a moderate, non‑speculative holding within broader equity portfolios.
